The Pistoia Alliance, a global, non-profit members鈥� organisation focusing on encouraging collaboration in the life sciences research and development (R&D) space, held its European Conference in London in mid-March.
This conference brought together Pistoia Alliance members, to discuss how technology can drive innovation and development in life sciences, and pharma specifically.
President of the Alliance Dr Steve Arlington explains: 鈥淔or us, in the broadest context of healthcare鈥� I can鈥檛 see all of these new technologies, artificial intelligence (AI), machine learning, blockchain, being successful if collaboration across all the players is not overt.鈥�
Professor Mark Caulfield, interim president of Genomics England, reiterated this sentiment, saying during his presentation that the industry鈥檚 role in helping humanity is 鈥渆nhanced by a future coalition of global intellects.鈥�
Caulfield urged industry representatives in attendance to take advantage of the huge data source resulting from 100,000 genomes project and now the NHS National Genomic Medicine Service, which aims to sequence five million genomes in five years as currently the 鈥渄ata is a long way from medicines.鈥�
The importance of data to life sciences R&D
The core themes discussed during the conference sessions were real world data and AI, the latter of which was primarily focused around the importance of both good quality and a large quantity data.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataArlington says: 鈥淭he theme of the conference has been, in essence, all about healthcare data. That data interface with the biology of drug discovery, with patient records, with genomes of both sick and viable healthy individuals.鈥�
Software company Databiology founder Les Mara described data as an 鈥渋ndustry commodity鈥� that needs to be exploited either now or never since it is a 鈥渕odern day gold rush.鈥�
Discussing how the industry could use real world data
Panellists from IQVIA, GlaxoSmithKline (GSK) and NICE debated the definition of and how to use real world data in drug development. GSK vice-president Andrew Roddam said: 鈥淚 have always hated the concept of real world data because it tries to put labels on something that isn鈥檛 actually there.鈥�
IQVIA鈥檚 senior vice-president of strategy and technology Ben Hughes added: 鈥淲hat is happening is that definitions of real world data and intellectual data are starting to break down.
Hughes continued: 鈥淲e are in a very early stage of regulators saying okay to these types of real world data鈥he barriers we have are that real world data can be very messy,鈥nd there are lots of places where we can鈥檛 use real world data.鈥�
鈥淏ut we expect it to happen a lot more鈥y guess is that in the next four to five years 20-30% of studies will have a real world component.鈥�
NICE senior scientific advisor Jacoline Bouvy explained how regulators view real world data: 鈥淭here are huge opportunities in the amount of data that is becoming more and more available because of the increased digitalisation.
鈥淗aving said that, there are challenges [and] it would be a mistake to think that real world data is a blanket solution to those challenges. It also is not a solution or a way to provide reimbursement to drugs or technologies 鈥without] cost-effectiveness.
鈥淚deally real world data would help us to understand how people progress, but in practice there are huge gaps [in the data sources]鈥t will be extremely difficult to answer questions about the added value that a new treatment provides without randomised control trial evidence available.鈥�
鈥淚f there is not a lot of uncertainty about the answer to the question鈥here might be that there is no need for monitoring or tracking.鈥�
Roddam commented on the lack of expertise in informatics within the NHS and the existence of legacy systems, as well as 鈥渘o great incentive process there to make it better.鈥�
Hughes, however, noted the significant progress that has been made: 鈥淲e haven鈥檛 stood still, we have achieved quite a lot, but we have to have realistic expectations about what health systems can do with data, because it鈥檚 not like they can reconfigure patient pathways on the fly.鈥�
Importance of data when using AI
Rather than focusing on the algorithms themselves, participants at the AI and machine learning event focused on the data side because as noted by Lifebit鈥檚 CEO Dr Maria Chatzou, 鈥�80% of AI is data.鈥�
She noted the importance of integrating data into a holistic system as having all your data in one place makes management of that data easier. This would be supported, in her view, by the creation of leadership and best guidelines to help companies solve any issues they have with data.
The Hyve鈥檚 Sjoerd van Hagen noted the need for clean, high quality data to use AI techniques most effectively and how solutions, such as his company鈥檚 Open Target Platform, which he is team leader for, provide incentives for groups to share their data in order to identify drug targets for certain diseases.
In terms of transparency surrounding data and creating public trust regarding the use of data in the life sciences space, which Arlington emphasises is of huge importance to the Pistoia Alliance and central to its work, van Hagen argues that pharma companies and their technological partners need to show and explain what they are doing with their data.
